OncologyBristol Myers Squibb
Bristol Myers Squibb Reports Phase 3 CheckMate-067 Results for Opdivo Plus Yervoy in Melanoma
BMI
Biotechnology Media Insights
Editorial Team · August 20, 2023
BMS announces Phase 3 CheckMate-067 trial results showing Opdivo plus Yervoy significantly improves overall survival vs ipilimumab alone in advanced melanoma.
Bristol Myers Squibb today announced results from the Phase 3 CheckMate-067 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo alone or Yervoy alone in patients with previously untreated advanced melanoma. The trial demonstrated that Opdivo plus Yervoy significantly improved overall survival compared to ipilimumab alone.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.